menu
    • menu
    [{"orgOrder":0,"company":"UCLA","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Cell and Gene therapy","year":"2020","type":"Funding","leadProduct":"CAR-T therapy","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"UCLA","amount2":0.01,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.01,"dosageForm":"","sponsorNew":"UCLA \/ National Institution of Health","highestDevelopmentStatusID":"1","companyTruncated":"UCLA \/ National Institution of Health"},{"orgOrder":0,"company":"University of California","sponsor":"AmbioPharm","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Peptide","year":"2021","type":"Not Applicable","leadProduct":"Thrixopelma pruriens venom peptide","moa":"","graph1":"Neurology","graph2":"Undisclosed","graph3":"University of California","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"University of California \/ AmbioPharm","highestDevelopmentStatusID":"1","companyTruncated":"University of California \/ AmbioPharm"},{"orgOrder":0,"company":"University of California","sponsor":"Avrobio","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"AVR-RD-04","moa":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"University of California","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"","sponsorNew":"University of California \/ University of California","highestDevelopmentStatusID":"7","companyTruncated":"University of California \/ University of California"},{"orgOrder":0,"company":"University of California","sponsor":"NemaLife","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","year":"2022","type":"Partnership","leadProduct":"Psychoplastogen","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"University of California","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"","sponsorNew":"University of California \/ University of California","highestDevelopmentStatusID":"4","companyTruncated":"University of California \/ University of California"},{"orgOrder":0,"company":"University of California","sponsor":"ABVC BioPharma","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Radix Polygalae Extract","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"University of California","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"University of California \/ University of California","highestDevelopmentStatusID":"8","companyTruncated":"University of California \/ University of California"},{"orgOrder":0,"company":"University of California","sponsor":"ABVC BioPharma","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Radix Polygalae Extract","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"University of California","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"University of California \/ University of California","highestDevelopmentStatusID":"8","companyTruncated":"University of California \/ University of California"},{"orgOrder":0,"company":"UCLA","sponsor":"Trethera","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"TRE-515","moa":"dCK","graph1":"Neurology","graph2":"Phase I","graph3":"UCLA","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"UCLA \/ UCLA","highestDevelopmentStatusID":"6","companyTruncated":"UCLA \/ UCLA"},{"orgOrder":0,"company":"University of California","sponsor":"University of California","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"Cyclophosphamide","moa":"duoCAR-T Cell","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"University of California","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"University of California \/ University of California","highestDevelopmentStatusID":"7","companyTruncated":"University of California \/ University of California"},{"orgOrder":0,"company":"University of California","sponsor":"Vanda Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"VPO-227","moa":"CFTR","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"University of California","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"University of California \/ University of California","highestDevelopmentStatusID":"6","companyTruncated":"University of California \/ University of California"},{"orgOrder":0,"company":"UCLA","sponsor":"CancerVAX","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Antibody","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"UCLA","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"UCLA \/ UCLA","highestDevelopmentStatusID":"2","companyTruncated":"UCLA \/ UCLA"},{"orgOrder":0,"company":"University of California","sponsor":"Aardvark Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Denatonium Acetate","moa":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"University of California","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"","sponsorNew":"University of California \/ University of California","highestDevelopmentStatusID":"8","companyTruncated":"University of California \/ University of California"},{"orgOrder":0,"company":"University of California","sponsor":"Myto Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Monomethyl Fumarate Prodrug","moa":"","graph1":"Rare Diseases and Disorders","graph2":"Preclinical","graph3":"University of California","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"","sponsorNew":"University of California \/ University of California","highestDevelopmentStatusID":"4","companyTruncated":"University of California \/ University of California"},{"orgOrder":0,"company":"University of California","sponsor":"National Institute on Aging","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2024","type":"Funding","leadProduct":"CNDR-51997","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"University of California","amount2":0.01,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"University of California \/ National Institute on Aging","highestDevelopmentStatusID":"14","companyTruncated":"University of California \/ National Institute on Aging"}]

    Find Clinical Drug Pipeline Developments & Deals by University of California

    Menu

    University of California

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            University of California

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            University of California

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CNDR-51997

                            Therapeutic Area : Neurology

                            Study Phase : Preclinical

                            Sponsor : National Institute on Aging

                            Deal Size : $6.9 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            NIH Awards $6.9 Million to Advance Potential Alzheimer’s Disease Treatment

                            Details : The proceeds will be used to prepare a potential disease-modifying Alzheimer’s treatment, CNDR-51997, which prevented tau from becoming detached from microtubules, for future clinical trials.

                            Brand Name : CNDR-51997

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            August 21, 2024

                            Lead Product(s) : CNDR-51997

                            Therapeutic Area : Neurology

                            Highest Development Status : Preclinical

                            Sponsor : National Institute on Aging

                            Deal Size : $6.9 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            UCLA

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            UCLA

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Antibody,CAR T Cell Therapy

                            Therapeutic Area : Oncology

                            Study Phase : Discovery

                            Recipient : CancerVAX

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            CancerVAX Reports Positive Progress on Kids Cancer Immunotherapy Treatment

                            Details : CAR-T cells and bispecific antibodies targeting this protein biomarker. The findings of this work will create and evaluate new promising tools for recruiting and activating the patient’s own immune system to track and destroy Ewing sarcoma tumors.

                            Brand Name : Undisclosed

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            June 12, 2023

                            Lead Product(s) : Antibody,CAR T Cell Therapy

                            Therapeutic Area : Oncology

                            Highest Development Status : Discovery

                            Recipient : CancerVAX

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            University of California

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            University of California

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Denatonium Acetate

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase II

                            Recipient : Aardvark Therapeutics

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Aardvark Therapeutics Reports Positive Phase II Clinical Data for ARD-101

                            Details : ARD-101 (denatonium acetate) is a first-in-class oral substantially gut-restricted with minimal systemic exposure yet conveys systemic effects via activation of GLP-1, GLP-2, and which show positive impact on hunger scores in general obesity and Prader-W...

                            Brand Name : ARD-101

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            June 12, 2023

                            Lead Product(s) : Denatonium Acetate

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase II

                            Recipient : Aardvark Therapeutics

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            University of California

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            University of California

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Monomethyl Fumarate Prodrug

                            Therapeutic Area : Rare Diseases and Disorders

                            Study Phase : Preclinical

                            Recipient : Myto Therapeutics

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            MYT-109, a Promising Treatment for Leigh Syndrome

                            Details : MYT-109 improves mitochondrial functions and rescues lethality in animal models of Leigh’s Syndrome. It’s a prodrug, using a proprietary technology, with improved PK compared to other fumarate based drugs.

                            Brand Name : MYT-109

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            November 29, 2022

                            Lead Product(s) : Monomethyl Fumarate Prodrug

                            Therapeutic Area : Rare Diseases and Disorders

                            Highest Development Status : Preclinical

                            Recipient : Myto Therapeutics

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            University of California

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            University of California

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : VPO-227

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I

                            Recipient : Vanda Pharmaceuticals

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Vanda Pharmaceuticals Announces Orphan Drug Designation Granted for VPO-227, a Novel Candidate for the Treatme...

                            Details : VPO-227 is a small-molecule with a novel mechanism of action which blocks the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) ion channel,in development for the treatment of secretory disorders, including cholera.

                            Brand Name : VPO-227

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            October 21, 2022

                            Lead Product(s) : VPO-227

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I

                            Recipient : Vanda Pharmaceuticals

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            University of California

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            University of California

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : LVgp120duoCAR-T cells,Cyclophosphamide

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I/ Phase II

                            Recipient : Caring Cross

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Caring Cross Announces Dosing of First Participant in Anti-HIV DuoCAR-T Cell Therapy Phase 1/2a Clinical Trial

                            Details : Initiation of the Phase 1/2a trial represents the first-in-human clinical study investigating a dual chimeric antigen receptor (duoCAR)-T cell therapy for the treatment of HIV.

                            Brand Name : LVgp120duoCAR-T cells

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            October 11, 2022

                            Lead Product(s) : LVgp120duoCAR-T cells,Cyclophosphamide

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I/ Phase II

                            Recipient : Caring Cross

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            UCLA

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            UCLA

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : TRE-515

                            Therapeutic Area : Neurology

                            Study Phase : Preclinical

                            Recipient : Trethera

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Trethera and UCLA Publish Data Demonstrating TRE-515 Ability to Control and Improve Multiple Sclerosis Symptom...

                            Details : TRE-515 is a first-in-class clinical stage drug that inhibits deoxycytidine kinase (dCK), the rate-limiting enzyme in the nucleoside salvage pathway, one of two biosynthetic pathways that generate DNA precursors.

                            Brand Name : TRE-515

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            September 07, 2022

                            Lead Product(s) : TRE-515

                            Therapeutic Area : Neurology

                            Highest Development Status : Preclinical

                            Recipient : Trethera

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            University of California

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            University of California

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Radix Polygalae Extract

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Phase II

                            Recipient : ABVC BioPharma

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            ABVC BioPharma Announces Enrollment Progress for ADHD Phase II Part 2 Clinical Study

                            Details : The enrollment progress for the Phase II part 2 clinical study of ABV-1505 (Radix Polygalae Extract). Since the first subject began treatment on May 10, 2022, 13 additional subjects have been enrolled in the study from a total of 23 subjects screened.

                            Brand Name : ABV-1505

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            June 01, 2022

                            Lead Product(s) : Radix Polygalae Extract

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Phase II

                            Recipient : ABVC BioPharma

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            University of California

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            University of California

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Radix Polygalae Extract

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Phase II

                            Recipient : ABVC BioPharma

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            ABVC BioPharma Completes Site Initiation Visits and Begins Enrollments for ADHD Phase II Part 2 Clinical Study

                            Details : PDC-1421, active ingredient of ABV-1505 and ABV-1504 , a plant based drug targeting ADHD symptoms in adults inhibit norepinephrine transporter (NET) for major depressive disorder.

                            Brand Name : ABV-1505

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            April 28, 2022

                            Lead Product(s) : Radix Polygalae Extract

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Phase II

                            Recipient : ABVC BioPharma

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            University of California

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            University of California

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Psychoplastogen

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Preclinical

                            Recipient : NemaLife

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            NemaLife and UC Davis Enter Into a Research Partnership to Test the Therapeutic Potential of Several Novel Psy...

                            Details : High-throughput platform will enable the Olson Lab to quickly examine the vast psychoplastogen chemical space in the search for new neurotherapeutics. This partnership will help to understand the complex chemical and pharmacological space occupied by psy...

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            April 19, 2022

                            Lead Product(s) : Psychoplastogen

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Preclinical

                            Recipient : NemaLife

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth